- Irene Bai MD, MPH is the CEO of MegaNano Biotech. Inc. She has more than 20 years of research experience including cancer biologist, epidemiologist, and biostatistician.
- Chuanhai Cao Ph.D. and MPH will serve as a technical consultant for MegaNano BioTech. Inc. Dr. Cao has over 25 years of research experience and five years of business experience.
- Jerry Chou President of Biomer Tech. Inc. CA: Jerry has over 20 years of business experience, and he will serve as a consultant for business development for the company.
- Ben Yu MD, general manager of MegaNano BioTech Inc. Who has more than 10 years of experience in the business.
Our US-based business is located in Tampa, Florida on the campus of the University of South Florida (USF Connect). We are operated by a group of researchers and scientists including cancer biologists, neuroscientists, chemists, and statisticians.
- Antibodies against cancer and neurological diseases
- ELISA kits for cancer and neurological diseases
- Therapies with nutraceuticals for Alzheimer’s disease (AD) and Parkinson’s disease (PD);
- Peptides: Amyloid beta (Aβ40, Aβ42) and Tau peptides (partnered with Biomer Tech Inc.);
- Antibodies: Anti-Aβ (40, 42)antibodies, anti-Alpha Synuclein antibodies, and anti-GPC1 antibodies, and well as anti-HIV gp41 and gp120 antibodies;
- Recombinant proteins: Recombinant Aβ, recombinant alpha synuclein, and GPC1 proteins et al;
- Sandwich ELISA kits quantitative detection for Aβ40, and 42, alpha synuclein, and GPC1 protein;
- ELISA kits for cytokines;
- Nano-formula of CBD, melatonin, and coffee for oral and intranasal spray;
- Dendritic cell vaccines for animal studies: Aβ-amyloid based vaccine for Alzheimer’s disease and alpha synuclein-based vaccine for Parkinson’s disease.
The novelty of the patent
We have licensed a patent through USF: “an antigen stimulation dendritic cell vaccine”. It is a platform for immunotherapies, such as we can develop for cancer and neurological diseases. The advantage of the dendritic vaccine can overcome aging-related immune tolerance and bridge the innate immunity and acquired immunity to control overreaction to a vaccine. Dendritic cell vaccines have been used in clinical trials for years and have shown no significant adverse effects.
- Using healthy donors’ blood instead of patients’ blood to generate the therapeutic vaccine;
- Using immature dendritic cells rather than matured dendritic cells to generate the vaccine;
- Using killed and lyophilized antigen-sensitized dendritic cells as the vaccine to open the availability of this cell-based treatment to patients around the world;
- This therapeutic vaccine applies to any antigen-related disease. It has been tested for Alzheimer’s disease and Parkinson’s disease treatment and is under testing for lung cancer and malaria.
Opportunities for Investment
- Vaccine development for the 2nd AD vaccine: We need $5-10 million to bring this vaccine to phase II clinical trial ($2 million to complete the IND application and $8 million to complete the phase I clinical trial). It will take about 2 years to complete the IND application and phase I clinical trial.
- The nasal spray will require $500,000 to bring the product to market (ratio of investment versus profit is 1:8). The formula is prepared, so the mass product can be produced immediately once the investment is in place.